ArticleVirus research2026
Calu-3 cells as novel efficient cell culture system for Borna disease virus 1 (BoDV-1).
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Borna disease virus 1 (BoDV-1) is the causative agent of zoonotic infections resulting in severe encephalitis with a high case-fatality rate in humans. To search for an efficient in-vitro cell culture system for the generation of BoDV-1 virus stocks, we compared different human cell lines (A549, Caco-2, Calu-3, oligodendroglioma cells, SK-N-AS) and Vero cells with respect to BoDV-1 infection kinetics. While all cell lines included in the study supported the release of BoDV-1 RNA and its intracellular accumulation at the end of the experiment, viral RNA was detected in the supernatant of Calu-3 cells as early as six days post infection. In addition, two weeks post infection RNA loads remained highest in the supernatant of this cell line, which also yielded highest BoDV-1 RNA copies per cell. Using the ratio of BoDV-1 RNA in the supernatant and the cell pellet as a surrogate marker, Calu-3 cells released BoDV-1 RNA most efficiently. Notably, favipiravir (T-705), a drug with a described cell-type dependent inhibitory activity against BoDV-1 in vitro, which has been used as an off-label therapy in some cases of human BoDV-1 infection, did not reduce BoDV-1 RNA shedding into the supernatant of permanently infected Calu-3 cells and had only a limited effect in a de-novo infection model. In conclusion, our results underline the broad viral tropism of BoDV-1 in vitro and first describe a high release efficiency for BoDV-1 RNA in Calu-3 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.